HC Wainwright reissued their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL - Free Report) in a report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $40.00 target price on the biotechnology company's stock.
Get Anavex Life Sciences alerts: Enter Your Email Address Anavex Life Sciences Price Performance Shares of Anavex Life Sciences stock traded down $0.09 during trading on Tuesday, hitting $3.70. 1,608,452 shares of the company's stock traded hands, compared to its average volume of 1,330,056. Anavex Life Sciences has a 1 year low of $3.25 and a 1 year high of $10.45. The stock has a market capitalization of $313.17 million, a P/E ratio of -7.40 and a beta of 0.67. The business has a 50-day simple moving average of $4.05 and a 200-day simple moving average of $5.59.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). During the same quarter in the previous year, the firm posted ($0.17) EPS. On average, equities analysts predict that Anavex Life Sciences will post -0.55 earnings per share for the current fiscal year.
Market Data 
Markets 
AI
